Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes participants with prolongation of QT‐interval on ECG compared with standard care or placebo (very low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes development of confirmed COVID‐19 at 14 days from enrolment compared with placebo (very low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes hospitalized due to COVID‐19c compared with placebo (very low certainty).
It is very uncertain whether siponimod changes number of participants with relapses at 6 months compared with placebo (very low certainty).
Siponimod may leads to lower participants with disability worsening at 6 months compared with placebo (low certainty).
Siponimod showed no clear difference in number of participants who withdrew due to AEs at 6 months compared with placebo (low certainty).
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).
It is very uncertain whether siponimod changes mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI… compared with placebo (very low certainty).
Siponimod may leads to lower mean number of new lesions or enlarged pre‐existing lesions on… compared with placebo (low certainty).
Siponimod showed no clear difference in number of participants with at least one SAE at 6 months compared with placebo (low certainty).
DPP4i showed no clear difference in cardiovascular mortality compared with placebo (high certainty).
GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).
GLP‐1RA showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (moderate certainty).
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).
GLP‐1RA showed no clear difference in hospitalisation for HF compared with placebo (high certainty).
GLP‐1RA may leads to lower worsening renal function compared with placebo (low certainty).
GLP‐1RA showed no clear difference in pancreatitis compared with placebo (low certainty).